ADVERTISEMENT

The Story Behind a Miracle Cancer Drug [Excerpt]

A new book tells the tale of Gleevec, a breakthrough treatment that targets cancer at the genetic level
Philadelphia Chromosome



From The Philadelphia Chromosome: A Mutant Gene and the Quest to Cure Cancer at the Genetic Level, by Jessica Wapner. Copyright © Jessica Wapner, 2013. Available wherever books are sold.

In The Philadelphia Chromosome journalist Jessica Wapner tells the story of the breakthrough cancer drug Gleevec, which has saved the lives of thousands of patients with chronic myeloid leukemia (CML) and other cancers since the U.S. Food and Drug Administration approved it in 2001. It was the first targeted cancer drug, developed after researchers identified the genetic mutation that gave rise to CML, and it set in motion the race to uncover the genetic roots of a wide range of cancers.

From The Philadelphia Chromosome: A Mutant Gene and the Quest to Cure Cancer at the Genetic Level, by Jessica Wapner. Copyright © Jessica Wapner, 2013. Available wherever books are sold.

Chapter 1: The First Clue
David Hungerford could not believe what he was seeing. He hovered over a microscope, turning the wheels this way and that to ensure the best view. A small glass slide was illuminated from below. It held a single cell that had been expanded and then stopped in the middle of reproducing, its forty-six chromosomes on full display. He checked and rechecked, and was absolutely certain: One of the chromosomes was too short.

It was 1959, and the field of genetic research was almost nonexistent. The 1956 confirmation of the standard number of chromosomes housed in the human cell—forty-six, in twenty-three pairs, one set inherited from each parent—hinted at something impossible to grasp, a continent on a horizon too distant to see with the tools of the day. Even though James Watson and Francis Crick had made their famous discovery of the helical structure of DNA in 1953 and the genetic root of Down syndrome—an extra copy of one chromosome—had been found the same year, the search for connections between DNA and disease had only just begun. Around the world, laboratories were just starting to toy with the kind of technology needed to explore genetic matter. Genes were units of heredity, a way for traits to be passed on from one generation to the next, including deficiencies. But how disease could possibly be linked to DNA was entirely unknown. Phrases like “genetic mutation” or “chromosomal abnormality” were not part of the vernacular yet because there was no need for such language.

And so it was that David Hungerford, a young scientist hovering over a microscope, was stunned by what he was seeing through the lenses. This was a man who knew how chromosomes should look. Camera-equipped microscopes were hot laboratory commodities in the 1950s, and Hungerford, an avid photographer, had gotten a job working with one in a Philadelphia cancer research center. He spent countless hours looking at the starfish-shaped chromosomes of the drosophila fly, training his eyes to see the fine banding patterns within. He was one of a handful of people alive at the time who could have spotted an anomaly among a blurry, inky array of chromosomes.

So it may have been inevitable that he’d ended up working with Peter Nowell, a doctor also in his early thirties doing cancer research across town at the University of Pennsylvania. In 1956, Nowell had accidentally stumbled upon a new method for seeing chromosomes inside cells. He had been studying blood cells from leukemia patients, his work following the usual approach of the day: rinsing the cells and staining them with a bluish-purple dye.

Science had come a long way in its ability to peer inside cells, the basic structural units inside every living thing, since they were first spotted by microscope in 1665. That discovery led to others, which led to the creation of cell theory, the notion that all living things are made of cells, and that new cells are made when old cells divide. But the cutting-edge techniques for seeing the inner clockwork were still rudimentary, calling for the scientist to squash a drop of cells on a covered glass slide with the thumb in order to put pressure on the cells. The squash was supposed to burst the cell, spilling out its gene-filled middle. But the approach failed as often as it succeeded, leaving behind broken cell fragments that were useless to researchers. People were frustrated with the technique, which wasted precious time and resources.

One day Nowell took a shortcut around the usual scientific procedure. “Pete was in a hurry, as young men tend to be,” Alice Hungerford, David’s wife, would recount years later. Instead of following a more rigorous cleaning method, Nowell washed a sample of white blood cells under some tap water. He dropped the rinsed cells onto the slide and was amazed by what he saw through the microscope. The tap water, it turned out, was hypotonic—a low-pressure solution that caused the cells to swell, like a deflated raft being blown up with too much air.

With the cells ballooned like that, Nowell could see something else equally surprising. It turned out that a bean extract he’d applied to help clot the red blood cells (making them easier to remove from a sample) had also stimulated division in the white cells. Captured in the midst of dividing, the cells were at their most expanded. Because the tap water had further expanded the size of the cell, the chromosomes had more room to spread out and were suddenly easier to see and count. No one was looking at chromosomes this way. Nowell hadn’t known it was possible. Then again, he knew nothing about genes and had little interest in genetics. But he kept the slide, figuring someone out there might be interested in taking a look.

The genetics community was small then, and the number of people in the Philadelphia area interested in genetic research could be counted on one hand. Hungerford heard about Nowell’s slide. The two began working together. For years, Nowell prepared slides that Hungerford would study under the scope. They perfected the hypotonic solution, still used in molecular genetics today, and figured out how to air-dry slides to help the cells spread out even more. But they saw nothing noteworthy.

Then, in 1959, three years after they’d met, there it was: an abnormally small arm of a worm-shaped chromosome inside a cell of a person with CML. With the chromosomes splayed in the squashed cell, Hungerford could clearly see that one was too small. A piece of it was missing. They looked at blood samples from six other CML patients and found the same abnormality.

Stunned, Hungerford snapped the camera shutter. He would not live to see the significance of the picture he’d just taken. In 1959, the effect that a single photograph showing a single mutant chromosome would have on the lives of countless patients and on the future of cancer treatment was entirely unsuspected.

“Until we stumbled over this Philadelphia chromosome, there was really no evidence that cancer might be due to genetic change,” Nowell, now 79, said decades later. This photograph would become the lasting portrayal of a moment when everything changed for cancer and medicine as a whole. It was the as-yet unrecognized starting point for the modern era of targeting cancer at its root cause.

Share this Article:

Comments

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Scientific American Special Universe

Get the latest Special Collector's edition

Secrets of the Universe: Past, Present, Future

Order Now >

X

Email this Article

X